Expression and purification of an NSD3-GB1 fusion protein as a way to study the structure of complex formation with Brd4 ET. by Tuokkola, Jennifer
Expression and purification of an NSD3-GB1 fusion 
protein as a way to study the structure of complex 
formation with Brd4 ET. 
Research Thesis 
Presented in partial fulfillment of the requirements for graduation with research distinction in 
Biochemistry in the undergraduate colleges of The Ohio State University 
by 
Jennifer Tuokkola 
 
The Ohio State University 
April 2020 
Project Advisor: Professor Mark Foster, Department of Chemistry and Biochemistry  
Introduction 
Brd4 
The Brd4 protein is a eukaryotic transcription factor belonging to the bromodomain and 
extraterminal domain (BET) family of proteins1. Brd4 is involved in both transcriptional and 
epigenetic regulation and its overexpression is heavily implicated in both carcinogenesis and 
tumor metastasis2.  
As is characteristic of the BET family, Brd4 has two bromodomains which are responsible for 
binding acetylated lysine residues. Brd4 has a preference to bind histones in hyperacetylated 
regions; this directs it to promoter and enhancer regions where it promotes transcription at 
both initiation and elongation steps2.  During transcription initiation, Brd4 acts as a kinase and 
phosphorylates Serine 2 on the RNA Polymerase II C-terminal domain (CTD)3. Brd4 also recruits 
PTEFb (positive transcription elongation factor) to promoters and activates its kinase subunit. 
PTEFb then phosphorylates CTD Serine 2 during productive elongation4.  
Studies have identified Brd4 target genes associated with multiple myeloma, colon cancer, lung 
cancer, prostate cancer, breast cancer, and more. This has made it a popular target in the field 
of cancer research. All current inhibitors of the BET family target the bromodomains by 
mimicking acetylated lysines and preventing Brd4 from binding to chromatin2. Bromodomains 
are not specific to the BET family, meaning these inhibitors do not target only the BET family.  
The extraterminal (ET) domain of Brd4 is specific to the BET family but remains unexplored as a 
therapeutic target. The ET domain is responsible for recruiting chromatin-modifying factors that 
result in transcriptional regulation and co-activation and also serves as a binding site for several 
viral factors5. Several structures have been solved of the ET domain in complex with peptides 
derived from these chromatin-modifying and viral factors, but the complete interactions have 
not been characterized.  
Previous work from the Foster Lab characterizes the structure of interaction between Brd4 ET 
and a peptide derived from murine leukemia virus (MLV) integrase using nuclear magnetic 
resonance (NMR)6. The structure shows the formation of a three-stranded antiparallel -sheet 
motif. This study goes on to indicate that MLV integrase can outcompete nuclear set receptor 
SET domain protein 3 (NSD3) for binding by the ET domain. This suggested a conserved 
mechanism of interaction between the ET domain and its binding factors involved in 
transcriptional activation.7 
NSD3 
NSD3 is a histone methyltransferase responsible for the 
methylation of lysine residue 36 on histone H3. This methylation 
results in looser binding of DNA by the histone, making the DNA 
accessible to replication and transcriptional machinery and 
thereby promoting cell cycle progression. Due to this role, NSD3 
has been shown to be imperative in the maintenance of acute 
myeloid leukemia (AML)8. The NSD3-short isoform is 645 amino acid residues and contains only 
the PWWP1 domain which is a chromatin reader domain. While this isoform lacks the 
 
Figure 1. Structure of Brd4 ET 
domain (green and red) 
bound to a peptide 152-
EIKLKITKTIQN-163 derived 
from NSD3 (orange)4 
methyltransferase activity of the long isoform, it effectively serves as an adaptor protein which 
couples Brd4 to the chromatin remodeler protein CHD89.  
Due to its relevance in transcriptional regulation and AML maintenance, the interaction 
between Brd4 ET and NSD3 has been studied. Previous studies showed that NSD3 residues 100-
263 were sufficient to maintain binding with the ET domain with an affinity of 2.1 M, 
measured by surface plasmon resonance (SPR)6. Subsequent studies using nuclear magnetic 
resonance indicated that residues 152-163 of NSD3 form an intermolecular β-sheet with the ET 
domain (Figure 1) with a reported Kd of 140 M7, measured by isothermal titration calorimetry 
(ITC). NSD3 residues 152-163 show sequence similarity with the ET binding region of MLV IN, 
yet the Kd of the peptide is almost 10 times higher than the longer construct, indicating that 
more than just residues 152-163 are involved in this interaction. Thus, the overall goal of my 
research is to determine the structure of the interaction between Brd4 ET and NSD3. This 
research will provide insight into an important biological interaction and will provide a valuable 
information on possible development of novel anti-cancer therapeutics which inhibit the BET 
family ET domain.   
GB1 
The first problem encountered in this project is that NSD3 100-263 did not remain soluble at 
the concentrations needed to characterize its structure using NMR spectroscopy. Our 
recombinant NSD3-expression construct was originally fused to a glutathione S-transferase 
(GST) tag to facilitate purification and maintain solubility during expression. However, the large 
size of GST (26.9 kDa) is incompatible with NMR 
structural studies, and GST must be removed 
prior to these experiments. Removal of the tag 
by treatment with the sequence-specific tobacco 
etch virus protease (TEV protease) resulted in 
immediate precipitation of NSD3 even when in 
complex with Brd4 ET. To determine if NSD3 
100-263 was the precipitate, an SDS-page gel 
was run showing GST-NSD3 alone and in 
complex with Brd4 ET (Figure 2).   The gel shows the disappearance of the product band 
corresponding to GST-NSD3 following TEV cleavage, indicating that it is no longer in solution.  
To combat this, GB1 was used as an alternative solubility tag.  GB1 is a 56 amino acid residue 
protein that originates from the B1 domain of Streptococcal protein G10. It has also been shown 
to increase the solubility of the proteins to which it is fused. The main benefit of using GB1 is 
that it has a well-defined NMR spectrum. This means that once fused, there is no need to 
 
Figure 2. SDS-PAGE gel verifying precipitate formation by NSD3 
when cleaved from GST tag. Lane 1: Size marker, Lane 2: GST-NSD3, 
Lane 3: TEV Protease, Lane 4: GST, Lane 5: Brd4 ET, Lane 6: GST-
NSD3 with Brd4 ET, before TEV cleavage, Lane 7: GST-NSD3 with 
Brd4 ET, after TEV cleavage.  
 
 
 
cleave the GB1 tag as long as its signals don’t overlap or convolute the spectrum of the NSD3-
Brd4 complex.  
NMR to Study Structure  
A 2D {1H, 15N} HSQC spectrum provides valuable structural information regarding protein 
structure and dynamics.  Each signal in a 1H-15N-HSQC spectrum arises from correlation 
between nitrogen and hydrogen, such as in the amide bond in the protein backbone. This 
means that each amino acid residue in a protein, with the exception of proline, will produce a 
peak on the spectrum. The position of each peak on the spectrum is characteristic of the 
chemical environment surrounding that amide Changes in peak position, referred to as 
chemical shift perturbations (CSPs), can be tracked upon the addition of a binding partner to 
determine which residues are interacting. 
To measure the interaction between Brd4 ET and NSD3, several spectra will be recorded. First, 
apo spectra of ET, NSD3-GB1, and GB1 alone will each be recorded. This provides reference 
spectra and allows for verification that the peaks arising from GB1 can be distinguished from 
the peaks arising from NSD3. Next, a spectrum will be recorded of the ET:NSD3 complex. The ET 
domain will be uniformly 15N-labeled, and NSD3-GB1 will be unlabeled. As 14N is NMR invisible, 
only peaks from the ET domain will be observed. CSPs upon the addition of NSD3-GB1 will be 
tracked. As signals from the ET domain have previously been assigned, these CSPs will indicate 
which residues of the ET domain are involved in the interaction. If residues beyond those 
reported to interact with NSD3 152-163 undergo significant CSPs, this will indicate an extended 
or additional interaction interface. These experiments could then be repeated with the ET 
domain unlabeled and NSD3-GB1 labeled to determine which residues of NSD3 are interacting 
with the ET domain. As all signals from NSD3 100-263 have not previously been assigned, 
additional triple resonance experiments will be performed to assign the peaks and map the 
CSPs. 
  
Materials and Methods 
Molecular Cloning 
NSD3 100-263 in pop5BT vector 
The gene sequence of NSD3 100-263 was amplified from bacterial vector pGEX-6P-1 (Sigma 
Aldrich GE28-9546-48) using the following primers: forward, 5’-CTTGTCGACTTTTGGCGCGGTGC 
GTAACTTCAG-3’ and reverse, 5’GCACGGCTGGTGGCTTCAATCGATTCTTAAGGGTT-3’. The PCR 
amplified product was purified and digested with SalI and EcoRI and cloned into these 
restriction sites of the pOP5BT vector (Addgene 112609) with an N-terminal GB1 protein and 
His tag (6x-His). There is a 7-residue linker (TGSGTSG) between the final residue of GB1 and the 
start of NSD3 100-263.  
 
Figure 3. Design of NSD3-GB1 in the pOP5BT vector. (A) The pOP5BT vector with restriction sites for the insertion of 
NSD3 100-263 highlighted. (B) Primers designed to amplify NSD3 100-263 from the pGEX-6P-1 vector. (C) The 
expected protein sequence of NSD3-GB1 in pOP5BT, GB1 is underlined in blue and NSD3 100-263 is underlined in 
orange.  
 
NSD3 100-263 in GEV 2 vector 
NSD3 100-263 was amplified from bacterial vector Puc57 (GenScript SD1176) using the 
following primers: forward, 5’-TTTGGATCCTTCGGTGCGGT-3’ and reverse, 5’-
GGCGCCCTGACTCGAG-3’. The insert was amplified using TD-PCR, purified, and digested with 
BamHI and EcoRI. It was cloned into these restriction sites of the GEV 2 vector (Addgene 12616) 
with an N-terminal GB1 protein and a C-terminal His tag.  
 
Figure 4. An overview of the GEV2 vector and the expected sequence of NSD3-GB1 in GEV2 with GB1 underlined in 
blue and NSD3 100-263 underlined in orange.  
 
Protein Expression and Purification  
Plasmids were transformed into electrocompetent E. coli BL21(DE3) cells by electroporation. 
Both plasmids are under control of an IPTG (isopropyl--thiogalactopyranoside) inducible 
promoter. To begin expression, a colony from a fresh transformation was picked and used to 
inoculate a 100 mL LB starter culture with 100 g/mL of carbenicillin, this culture was grown 
overnight at 37C with shaking. To express unlabeled protein, 20 mL of the starter culture was 
added to 1 L of LB media with 100 g/mL of carbenicillin. This culture was grown at 37C with 
shaking while the OD600 was measured. To express uniformly [U-15N]-labeled protein, 20 mL of 
the starter culture was added to 1 L of M9 minimal media containing 1 g/L 15N-ammonium 
chloride (Cambridge Isotope Laboratories, Inc.) as the sole nitrogen source. 
For the NSD3-GB1 in GEV2 vector, the best induction was observed when IPTG was added to a 
final concentration of 1 mM when the OD600 was 0.6. Following induction, the protein 
continued to grow at 37C for 6-8 hours before being harvested by centrifugation at 5000 rpm 
using Sorvall SLA-3000 rotor for 20 minutes at 4C.  
For the NSD3-GB1 in pOP5BT vector, several conditions were tested for induction of the 
protein. IPTG concentrations ranging from 0.4-1 mM were tested and induction temperatures 
of 37 C, 30 C, and 20 C were tested, but induction was not observed with any condition 
tested. Despite not observing induction, the protein was still harvested in the same way as 
listed above and purified.  
To fulfill the goal of obtaining an NMR spectrum of GB1 by itself, the pHLIC GB1 vector was 
used. This vector was a gift from the Magliery laboratory at The Ohio State University. GB1 was 
expressed in the same way as described above and induced to a final concentration of 1 mM 
IPTG when the OD600 was between 0.6-0.7.  
To uniformly label these with 15N, they were grown in defined minimal media. To make the 
minimal media, 9.465 g Na2HPO4, 0.18 g KH2PO4, and 1 g 15NH4Cl are dissolved and autoclaved 
in 1 L of ddH2O. Before inoculating the culture, you must also add: 100 L 1M CaCl2, 2 mL 1M 
MgSO4, 10 mL Gibco MEM Vitamin Solution (100x), 4 g glucose, 1 mL 1000x trace metal mix (50 
mM FeCl3, 20 mM CaCl2, 10 mM MnCl2, 10 mM ZnSO4, 2 mM CoCl2, 2 mM CuCl2, 2 mM NiCl2), 
and carbenicillin to a final concentration of 100 g/mL. Following inoculation, these cultures are 
grown, induced, and harvested in the same manner as listed above.  
To purify these proteins, the cell pellet is removed from the -80C freezer and thawed on ice. 
After it is thawed, the pellet is dissolved in 35 mL Lysis Buffer (20 mM NaPO4, pH 7.0, 500 mM 
NaCl, 15 mM imidazole) and 500 L 10 mM phenylmethylsulfonyl fluoride (PMSF). A complete 
mini protease tablet is also added to the cells. Cells are lysed by sonication following a cycle 
time of 5 minutes with 5 seconds on and 2 seconds off. The sonication step is generally 
repeated two times. Following sonication, the cells are centrifuged at 15,000 rpm using Sorvall 
SS-34 rotor for 45 minutes at 4C. The supernatant is then filtered through a 0.45-micron filter 
and then loaded onto the appropriate column.  
Both constructs mentioned above contain a His-tag, so a Ni column is used for purification. A 5 
mL HisTrap FF column from GE healthcare was used for all purification. The column was 
stripped of metal by washing with 25 mL 0.5 M EDTA, washed with 10 mL H2O, and charged 
with 25 mL of 100 mM NiSO4. The column was then equilibrated with 25 mL of lysis buffer. All 
samples were loaded onto the HisTrap FF column using a peristaltic pump at a flow rate of 5 
mL/min.  
In the case of NSD3-GB1 in pOP5BT vector, all purifications were done using a peristaltic pump 
with an isocratic elution. After loading the sample, the column was washed with 35 mL of lysis 
buffer and then eluted with 25 mL of elution buffer (20 mM NaPO4, pH 7.0, 500 mM NaCl, 500 
mM imidazole). This elution was concentrated to 1 mL using an Amicon centrifugal filter with 
MWCO of 10 kDa by centrifuging at 5000 rpm using Sorvall SS-34 rotor at 4C. The sample was 
further purified on a HiLoad 16/60 Superdex 75 (GE Healthcare) in 20 mM NaPO4, pH 7.0, and 
500 mM NaCl. Fractions containing the protein, as assayed by SDS-PAGE were collected and 
prepared for NMR.  
Free GB1 was also purified on a HisTrap FF column as described above. The elution from this 
column was concentrated to 10 mL and dialyzed overnight with 200 µL of 200 mM TEV protease 
in buffer containing 20 mM NaPO4, pH 7.0, and 500 mM NaCl The TEV protease removed the 
His-tag from GB1. The TEV protease used contained a His-tag so following dialysis, the dialysate 
was run on a second HisTrap FF column. This time, GB1 came through in the wash step and TEV 
protease came off in the elution. To ensure its purity, GB1 was also run on an S75p size 
exclusion column and the fractions from this column were collected and prepared for NMR.  
In the case of the NSD3-GEV2 construct, several difficulties were encountered during its 
purification. After loading onto the HisTrap FF column, a gradient elution was set up to reach a 
final concentration of 100% elution buffer over 10 column volumes. The complex elutes off the 
column at extremely low concentrations of imidazole with no separation of protein 
components. To combat this, the lysis buffer was remade with 0 mM imidazole and the elution 
buffer was remade with only 100 mM imidazole. There was still no separation of protein 
components seen during this purification.  
NMR 
To prepare samples for NMR, their concentrations were first tested. Both free GB1 and NSD3 in 
pOP5BT vector contain sufficient tryptophan and tyrosine residues to check their 
concentrations by absorbance at 280 nm. All samples used for NMR had a concentration 
around 100 M. The samples were then buffer exchanged into NMR buffer (10 mM NaCl, 5 mM 
DTT, 20 mM d11-Tris, pH 7.0) using a PD-10 desalting column. The samples were then 
concentrated to approximately 1 mL. In the NMR sample tube, 475 L of sample were 
combined with 50 L D2O and 1 L DSS. All NMR spectra were collected on a Bruker 600 MHz 
instrument. Raw data was processed using NMRFx and peak assignments were competed using 
NMRViewJ11.  
Results and Discussion 
Cloning, Expression, Purification, and NMR Spectroscopy of NSD3-GB1 in pOP5BT Vector 
Amplification of NSD3 100-263 from pGEX-6P-1 vector was verified via agarose gel. Controls of 
both restriction enzymes were done by showing linearization of plasmid DNA when digested by 
only one enzyme. Despite this, all ligation attempts of NSD3 100-263 into the pOP5BT vector 
were unsuccessful. Two ligase enzymes were tested with multiple incubation times and ratios 
of insert to vector. After many failed ligation attempts, cloning of NSD3 100-263 into the 
pop5BT vector was ultimately performed by GenScript.  
NSD3-GB1 in pOP5BT vector was expressed and purified as described in Materials and 
Methods. Figure 5 shows the expression and purification of NSD3-GB1. Throughout the 
induction process, there is no change in the band intensity corresponding to the protein despite 
being under the control of an IPTG-inducible promoter. NSD3-GB1 in pOP5BT has an expected 
molecular weight of 27 kDa but runs much higher on SDS-PAGE. This may be caused by a high 
number of aspartate and glutamate residues (15% overall composition) or proline residues 
(10% overall composition) in the protein. There may also be a mutation in the construct that 
results in the molecular weight being higher.  
 
Figure 5. Cloning, expression and purification of NSD3-GB1 in pOP5BT monitored by agarose gel and SDS-PAGE.  
(A) The gel on the left shows the restriction digest control done of the pOP5BT vector. Lane 1: Size marker, Lane 2: 
Undigested pOP5BT vector, Lane 3: SalI digested vector, Lane 4: EcoRI digested vector. The gel on the right shows 
the amplification of NSD3 100-263. Lane 5: Size marker, Lanes 6-9: PCR-Amplified NSD3 100-263.  
(B) Expression of GB1-NSD3 in pOP5BT in E. coli BL21(DE3) and purification using the HisTrap FF column. Lane 1: 
MW marker, Lanes 2-3: Cells before induction with 0.5 mM IPTG, Lanes 4-5: Cells 1 hour post-induction, Lanes 6-7: 
Cells 2 hours post-induction, Lane 8: Soluble fraction following sonication, Lane 9: Insoluble fraction following 
sonication, Lane 10: Ni column flow-through and wash, Lane 11: Ni column elution. 
Purification of NSD3-GB1 in pOP5BT yielded 500 μL protein with concentration of 91 M, 
measured by the A280. This sample was prepared for NMR as described in materials and 
methods and a 1H-15N-HSQC was recorded. Upon overlay with the GB1 spectrum, several peaks 
arising from GB1 could be assigned, however the spectrum shows that NSD3 100-263 is not 
folding properly. The overlapping peaks in the middle of the spectrum indicate lack of chemical 
shielding caused by secondary structure interactions. It is possible that the location of GB1 in 
the construct was preventing NSD3 100-263 from folding properly and induction of the 
construct was never observed, so NSD3 100-263 was cloned into an alternate GB1-encoding 
vector.   
 
Figure 6. Two-dimensional {1H, 15N}- HSQC spectrum of [U-15N-NSD3-GB1 from pOP5BT recorded at 600 MHz. GB1 
peak assignments made from pHLIC GB1 spectrum (Figure 10). 
 
Cloning, Expression, and Purification of NSD3-GB1 in GEV2 Vector  
In an attempt to achieve better protein induction a different GB1-encoding vector was tested, 
GEV2. NSD3 100-263 was amplified from the Puc57 vector using touchdown (TD) PCR. This 
amplification was verified with an agarose gel. The amplified and double digested NSD3 100-
263 was ligated with the double digested GEV2 vector to create the recombinant NSD3-GB1 in 
GEV2 vector. The results of the ligation vector were verified via Sanger Sequencing (Figure 7). 
Protein expression was optimized as described in Materials and Methods and induction of the 
product band is observed on an SDS-page gel. The crude lysate was loaded onto the HisTrap FF 
column, but the target protein eluted at very low imidazole concentrations (< 100 mM 
imidazole). As a consequence, there is no separation seen between proteins in the crude lysate 
when purification is done via Ni affinity chromatography, as shown in figure 8. While hexa-
histidine tagged constructs can have varying affinity to the Ni resin, it is unexpected to have 
such low affinity that no separation from crude lysate is observed. A possible explanation for 
this low affinity is that this tag is not completely exposed and to interact with the Ni resin. 
 
Figure 7. The expected sequence of NSD3-GB1 in GEV2 shown on the left with chromatograms from Sanger 
Sequencing on the right, verifying the sequence of the ligated construct.  
 Figure 8. Expression of NSD3-GB1 in GEV2 monitored by SDS-PAGE. Lane 1: MW Marker, Lanes 2-3: Cells before 
induction with 1 mM IPTG, Lanes 4-5: Cells after induction, Lane 6: Insoluble fraction following sonication, Lane 7: 
Soluble fraction following sonication, Lane 8: Ni column flow-through, Lanes 9-11: Ni column elution fractions.  
 
Expression, Purification, and NMR Spectroscopy of pHLIC GB1 
Free GB1 was expressed and purified as described in Materials and Methods. Figure 9 outlines 
the expression and purification process of GB1.  
 
Figure 9. SDS-PAGE gels outlining the expression and purification process of GB1. Lane 1: Protein Marker, Lanes 2-
3: pre-induction samples, Lanes 4-5: post-induction samples, Lane 6: insoluble fraction, Lane 7: insoluble fraction, 
Lane 8: Ni column flow-through, Lanes 9-13: Ni column elution fractions, Lane 14: Ni column flow-through following 
TEV cleavage, Lane 15: Ni column elution following TEV cleavage, Lanes 16-19: S75p size exclusion fractions. 
The fractions from the size exclusion were concentrated to 500 L and their concentration was 
determined to be 97 M. The sample was prepared for NMR and an HSQC was recorded. Peak 
assignments were made based on WT GB1 assignments published in the Biological Magnetic 
Resonance Data Bank (BMRB 25909). pHLIC GB1 was expected to have 60 amino acids following 
TEV cleavage with 3 asparagine residues and 1 glutamine residues. 63 total peaks were 
identified and 57 of them were assigned. Figure 10 shows the labeled HSQC with the assigned 
peaks.  
 
Figure 10. 2D {1H, 15N}- HSQC spectrum of 15N labeled GB1 protein recorded at 600 MHz. 
Conclusion and Next Steps 
Although NSD3 100-263 did not appear folded in the 1H-15N-HSQC, the GB1 tag was successful 
at keeping NSD3 100-263 soluble for purification. The design of a construct in the pOP5BT 
vector appeared to inhibit the folding of NSD3 100-263, making its spectrum indistinguishable. 
The GEV2 vector holds promise in allowing proper folding of NSD3 100-263 but purification of 
this construct needs to be optimized.  
It is also a possibility that NSD3 100-263 does not have secondary structure. There is no solved 
structure of this peptide, and it is predicted that even NSD3 152-163 is unstructured before 
binding ET. Although NSD3-GB1 in pOP5BT does not show a well-defined secondary structure 
on its HSQC, it there is a possibility that it may adopt a secondary structure when in complex 
with Brd4 ET. This could be monitored by taking the HSQC of NSD3-GB1 in pOP5BT while it is in 
complex with ET. This would give better insight into if the GB1 tag is interfering with any 
possible secondary structure formation.   
Due to the problems faced involving expression and purification of NSD3-GB1, there is an 
option to clone NSD3 100-263 into the pHLIC GB1 vector. Free GB1 in this vector showed good 
induction and simple purification by Ni affinity chromatography. The pHLIC vector offers cloning 
sites so NSD3 100-263 could be inserted with the GB1 tag on the N-terminus.  
Overall, characterizing the complete interaction between ET:NSD3 holds promise for directing 
future development of cancer therapeutics. ET demonstrating a conserved mechanism of 
interaction would open up many possibilities in terms of specific targeting of the BET family.  
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